(Q46408189)

21 December 2017

title

Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects (English)

1 reference

21 December 2017

1 reference

1 reference

Kyoung-Ah Kim

1

1 reference

21 December 2017

Pil-Whan Park

series ordinal

2

1 reference

21 December 2017

Ji-Young Park

series ordinal

3

1 reference

21 December 2017

publication date

1 May 2009

1 reference

21 December 2017

published in

Chirality

1 reference

21 December 2017

volume

21

1 reference

21 December 2017

issue

5

1 reference

21 December 2017

page(s)

485-491

1 reference

21 December 2017

The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

The metabolism and pharmacokinetics of amlodipine in humans and animals

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Coupled-column chromatography on a Chiral-AGP phase for determination of amlodipine enantiomers in human plasma: an HPLC assay with electrochemical detection

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Determination of the absolute configuration of the active amlodipine enantiomer as (-)-S: a correction

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Pharmacokinetic behaviour of R-(+)- and S-(-)-amlodipine after single enantiomer administration

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Enantioselective disposition of oral amlodipine in healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Pharmacogenomics: translating functional genomics into rational therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

The genetic determinants of the CYP3A5 polymorphism

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Stereoselective pharmacokinetics of amlodipine in elderly hypertensive patients

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Liquid chromatography-tandem mass spectrometry in chiral study of amlodipine biotransformation in rat hepatocytes

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects.

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine formulations in healthy adult male Korean subjects

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients1

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

1 reference

https://api.crossref.org/works/10.1002%2FCHIR.20588

7 January 2021

Identifiers

DOI

10.1002/CHIR.20588

1 reference

21 December 2017

1 reference

21 December 2017